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Blood plasma phosphorylated-tau isoforms track
CNS change in Alzheimer’s disease
Nicolas R. Barthélemy1, Kanta Horie1, Chihiro Sato1, and Randall J. Bateman1,2,3
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic
accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently
reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and
symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms
to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as
previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found
between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for
amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92),
p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC
= 0.75).
Introduction
Tests of central nervous system (CNS) proteins found in blood
plasma are being developed to enable simplified and inexpensive
testing compared with the current gold standards of cerebro-
spinal fluid (CSF) and brain positron emission tomography
(PET) imaging in Alzheimer’s disease (AD) and other neurode-
generative diseases. Brain and CSF proteins are transferred
across the blood brain barrier and arachnoid granulations to
the blood (Roberts et al., 2014), where the CNS proteins are
diluted in a complex mixture of other biomolecules. Over the
past few years, different studies have demonstrated CNS
disease-associated protein alterations could be detected in
blood. However, low amounts within a complex matrix, pe-
ripheral alterations, and peripheral expression of corre-
sponding proteins may reduce the accuracy of the biomarker
compared with its measurement in CSF.
Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with
accuracy change on Aβ42/40 ratio detected in CSF and associates
with measures of brain amyloid plaques by amyloid PET scans
(Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).
Neurofilament light (NfL) chain protein can be detected in blood
and tracks neuronal damage in several neurological diseases
(Bacioglu et al., 2016) similarly to CSF NfL (Preische et al., 2019).
NfL changes are detected around the time of symptom onset,
over a decade after abnormal AD amyloidosis is detectable by
brain imaging or CSF Aβ 42/40 (Bateman et al., 2012; Fagan
et al., 2014; Preische et al., 2019).
Tau is the second marker of AD pathology. Tau is a
microtubule-binding protein that is increased and phosphorylated
in AD and constitutes the main component in AD tangle and
neurite pathology. Total tau (t-tau) and some phosphorylated-tau
(p-tau) isoform levels are significantly increased in AD CSF.
However, plasma tau and CSF tau levels poorly correlate with each
other, creating a challenge in developing plasma tau as a bio-
marker for AD (Zetterberg et al., 2013; Mattsson et al., 2016).
Recent reports using immunoassays have suggested more prom-
ising developments; for example, some reports indicated slight
increases in plasma t-tau in mild cognitive impairment (MCI) and
AD (Mielke et al., 2017, 2018), and several studies demonstrated
plasma p-tau at threonine 181 (p-tau-181) increases in AD at MCI
andmoderate stages (Tatebe et al., 2017; Mielke et al., 2018). Blood
p-tau-181 can differentiate AD patients from other tauopathies at
symptomatic stages of AD with accuracy (Janelidze et al., 2020a;
Thijssen et al., 2020).
Our laboratory developed mass spectrometry (MS) measures
to accurately quantify both t-tau and multiple p-tau isoforms.
Using this approach, we previously identified that certain p-tau/
t-tau ratios are specifically increased in AD (Barthélemy et al.,
2019, 2020a). Remarkably, we have reported that CSF tau
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phosphorylation measures on threonine 217 (p-tau-217) are
closely associated with amyloidosis, improving identification of
amyloidosis at the asymptomatic stage (Barthélemy et al., 2015,
2017 Preprint, 2018). CSF hyperphosphorylation of p-tau-T217 is
more accurate than other sites, such as T181 (Barthélemy et al.,
2020b; Janelidze et al., 2020b) and T205 (Barthélemy et al.,
2020a), to detect the presence of amyloid plaques. Phosphoryl-
ation occupancy on T217 is also lower intracellularly than ex-
tracellularly in CSF (Barthélemy et al., 2019). Together, these
findings suggest that an increase of p-tau-217 in both normal and
AD CSF would be related to selective release of this isoform from
the CNS to CSF and that increased p-tau-217 release is closely
related to amyloid plaques.We hypothesized p-tau-217 is specific
to CNS, would cross the blood brain barrier, specifically con-
tributes to plasma level, and increases together with CSF
changes. In this study, we sought to quantify blood plasma tau
and p-tau species by MS, especially p-tau-217, to compare with
AD pathology and assess their potential as blood-based AD
biomarkers.
Results and discussion
Tau isoforms can be purified and enriched from plasma
We designed MS assays to assess plasma tau isoforms, including
plasma p-tau-217. Estimated concentrations of t-tau (1–20 pg/ml;
Zetterberg et al., 2013; Mattsson et al., 2016; Mielke et al., 2017)
and p-tau-181 (sub pg/ml; Tatebe et al., 2017), as reported by
immunoassays in plasma, are low and present a challenge for
measuring plasma tau using MS techniques. Moreover, p-tau-
217 in CSF is approximately five times less abundant than p-tau-
181 (Barthélemy et al., 2019). The sub pg/ml range estimated for
p-tau-217 measurement is far below the concentration of cur-
rently monitored plasma biomarkers (Geyer et al., 2017), in-
cluding the recently assayed plasma Aβ42 peptide using MS
(Ovod et al., 2017; Nakamura et al., 2018).
To overcome MS limitations in sensitivity (low attomolar
range), we designed an enrichment protocol to purify and con-
centrate plasma tau from 20 ml of plasma to 25 µl of final ex-
tract, leading to an enrichment factor of ∼800 times. This
protocol relies on an initial step of plasma protein precipitation
using perchloric acid to remove a majority of plasma proteins
such as albumin and immunoglobulins. Soluble tau in the su-
pernatant was concentrated using solid phase extraction as
previously reported (Barthélemy et al., 2016). The pellet ob-
tained after drying the solid phase extract was subsequently
immunopurified against N-terminus and mid-domain tau anti-
bodies as described previously (Sato et al., 2018). This multiple-
step extraction significantly decreased plasma interference on
minor phosphorylated peptide signals. Both plasma and CSF
were analyzed for t-tau and p-tau peptides by a highly sensitive
and resolute mass spectrometer equipped with nano-flow cap-
illary liquid chromatography interfaced with nano-electrospray
ionization (Barthélemy et al., 2019).
Plasma tau is truncated similar to CSF profiles
We used nano liquid chromatography coupled to tandem mass
spectrometry (nanoLC-MS/MS) to assay plasma samples from a
cohort of 34 participants enrolled during our tau stable isotope
labeling kinetics (SILK) study and characterized samples for
their plasma and CSF tau isoforms profile. The tau SILK protocol,
previously designed for measuring the half-life of tau (Sato et al.,
2018), includes the collection of large volume of blood at the time
of the tracer infusion. Among all investigated samples, 15 tau
peptides from residues 6–254 were detected including 0N-, 1N-,
2N-, and 3R-specific peptides. Inferred abundance of 0N/1N/2N
peptides indicated similar contributions to what was previously
reported in brain and CSF (∼5/5/1, respectively; Sato et al.,
2018). Notably, no peptides after residues 254 (except a 3R
peptide found in low abundance at residues equivalent to
306–317 residues in 2N4R tau) were detected, suggesting plasma
tau does not contain detectable levels of full-length tau. Plasma
tau peptide abundances dropped significantly after residue 221
(Fig. 1) as previously reported in CSF (Barthélemy et al., 2016;
Sato et al., 2018; Cicognola et al., 2019), suggesting a similar tau
truncation pattern in plasma as reported after release by neu-
ronal cells (Sato et al., 2018).
Tau phosphorylated peptides are identified in plasma extracts
by MS
Phosphorylated peptides on T181, S202, and T217 from the tau
mid-domain were quantified in all plasma extracts. For samples
with the lowest abundance signals for the phosphorylated pep-
tides, liquid chromatography (LC)–MS signals obtained for
p-tau-181, p-tau-202, and p-tau-217 were approximately seven,
three, and two times above the lower limit of quantification
(respectively at 0.2, 0.3, and 0.05 pg/ml). Phosphorylated pep-
tide at T217 was quantified in controls at an average concen-
tration of 0.13 pg/ml (28 amol/ml; Table 1). To our knowledge,
this is the lowest concentration ever measured by MS for a
protein marker in human plasma. Phosphorylated T205 peptide
was inconsistently detected in 19 of the 34 samples below the
lower limit of quantification (0.3 pg/ml) and was not included in
further analyses. Other low abundant phosphorylated sites
previously reported by MS in CSF (Barthélemy et al., 2019) at
T153, T175, S199, S208, S214, and T231 were not detected in the
plasma extracts.
Plasma p-tau-217 and p-tau-181 correlate with CSF tau
isoforms changes
No correlation was found between CSF and plasma t-tau levels
as previously reported by immunoassays (Zetterberg et al., 2013;
Mattsson et al., 2016). However, a high correlation was found
between CSF and plasma p-tau-217 measures (Fig. 2 A and
Table 2; p-tau-217 absolute level and pT217/T217 ratio, Spearman
rho 0.78 and 0.78, respectively, for all cohorts). Also, a signifi-
cant correlation was found between CSF and plasma for p-tau-
181 measures as previously reported (Janelidze et al., 2020a;
Thijssen et al., 2020; Table 2; p-tau-181 absolute level and pT181/
T181 ratio, Spearman rho 0.68 and 0.68, respectively, for all
cohorts). No correlation was found between CSF and plasma
measures of pS202. All significant CSF/plasma correlations were
mainly driven by amyloid-positive participant values since no
correlations were found in amyloid-negative groups (not
shown). Consistently, plasma p-tau-217 and p-tau-181 measures
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recapitulated separations obtained in CSF between amyloid-
positive and -negative participants regardless of their cogni-
tive status (Fig. 1 and Table 2; area under the curve (AUC) in CSF
and plasma respectively 1.00 and 0.98 for pT217/T217; 0.95 and
0.98 for p-T181/T181). Together, these data suggest that plasma
p-tau-217 and p-tau-181 can act as proxies for changes in CNS-
soluble tau and thus serve as useful biomarkers.
Changes in plasma p-tau-217 have a larger dynamic range than
p-tau-181 in AD
We calculated the magnitude of change in plasma tau isoforms
between controls and different amyloid clinical groups (Table 2).
In CSF, the highest difference in amplitude between amyloid-
positive individuals and controls was found for the level of
p-tau-217 (+800%) group followed by the p-tau-181 (+250%)
group. However, these changes were partially due to the con-
comitant contributions of CSF tau isoform increases as mea-
sured for t-tau level (+190%). When normalized from tau
variation using the p-tau/t-tau ratio, pT217/T217 demonstrated a
greater change than pT181/T181 (+220% vs. +25%). In plasma, the
high magnitude of increase for p-tau-217 in the amyloid-positive
group remained higher than p-tau-181 measurements in all of
the clinical groups (from +230% to +340% for pT217/T217 and
from +60% to +80% for pT181/T181). Importantly, CSF and
plasma p-tau-217 measures (Table 1 and Fig. 2, B and C) distin-
guished amyloid-positive, tau PET–negative participants from
controls. This suggests that p-tau biomarkers are changed before
detectable tau aggregation and reflect abnormal soluble tau
metabolism occurring concomitantly with brain Aβ pathology.
Plasma p-tau modifications are detected in a validation cohort
using lower plasma volume
To validate the discovery results in a larger cohort, we modified
the plasma extraction method to downscale the volume of
plasma needed to 4 ml. This assay provided sufficient sensitivity
and reproducibility for measuring endogenous plasma p-tau
levels (Fig. S1 and Table S1). We measured CSF and plasma for
t-tau, p-tau-181, and p-tau-217 in 92 participants enrolled in Aβ
SILK studies and selected according to their amyloid and
cognitive status (Patterson et al., 2015; Ovod et al., 2017). Mea-
sures of p-tau-217 remained specific to amyloid status (Fig. 3, B
and C; and Table 2; area under receiver operating curve
[AUROC] 0.92 and 0.93 for ratio and level, respectively) and
correlated with CSF (Fig. 3 A and Table 2; r = 0.79 and 0.70) and
PET amyloid (Table 2; r = 0.70 and 0.67). PT217/T217 provided
reasonable separation of amyloid-positive and -negative groups
cognitively unimpaired (AUC 0.86). The p-tau-181 measures
were less specific than in the discovery cohort in differentiating
amyloid groups (Fig. 3, E and F; AUROC 0.75 and 0.72 for ratio
and level, respectively). Again, no significant increase of plasma
t-tau was observed (Fig. 3 D). For this larger cohort, the better
performance for amyloid detection of p-tau-217 measures over
p-tau-181 observed in CSF (Fig. 3 G) was recapitulated in plasma
(Fig. 3 H). Plasma pT217/T217 was inversely correlated with CSF
Aβ 42/40 as expected with normal Aβ levels associated with low
pT217 phosphorylation (Fig. 3 I).
Peripheral tau phosphorylation status is different from both
control and AD CNS tau
The absence of correlation between CSF and plasma t-tau levels
(Table 2) suggests that the main origin of plasma t-tau is from
peripheral sources, not the CNS. From previous reports, plasma
t-tau levels reflect CNS tau changes only when significantly
increased compared with baseline, for example, in patients with
acute stroke, brain injury (Bulut et al., 2006; Neselius et al.,
2013; Bogoslovsky et al. 2017; Rubenstein et al., 2017), brain
metastases, (Darlix et al., 2019) and likely AD patients with high
CNS t-tau release (Kasai et al., 2017; Mielke et al., 2018). Thus,
tau released in the CNS would contribute to significant plasma
t-tau increases only when its contribution becomes much higher
than the peripheral tau contribution.
The higher contribution of peripheral tau over CNS tau in
plasma is also supported by the difference observed in p-tau/tau
ratios between CSF and plasma (Table 2). Both pT217/T217 and
pT181/T181 ratios are significantly decreased in plasma com-
pared with CSF. This observation supports the dilution of CNS
tau in peripheral tau, with much lower p-tau-217 and slightly
lower p-tau-181 abundance (Table 2, a decrease of 4.6 and 1.8
Figure 1. Plasma tau truncation profile after
chemical extraction and IP in the discovery
cohort. Left: Plasma tau peptides concentration
profiles obtained from the 36 individuals. Each
line corresponds to the peptide profile from one
participant. Right: Dots represents averaged tau
peptides normalized concentration obtained
from the overall cohort. Normalized concentra-
tion for each peptide is relative to the sum of the
peptides concentrations measured in each par-
ticipant. Bars represent SD. Label a indicates a
decrease of 2N and 1N+2N peptide abundance
consistent with 5/5/1 0N/1N/2N contribution in
plasma tau. Label b indicates a decrease con-
sistent with the presence of around 10% of
phosphorylation on position 181. Phosphoryla-
tion on T181 induces a trypsin missed cleavage between residues 180 and –181. This contributes to a decrease of 175–180 and 181–190 peptides abundance
proportional to the extent of phosphorylation on T181. Label c indicates a decrease consistent with tau truncation between residues 221 and 226. Cicognola
et al. (2019) have reported CSF tau main cleavage occurring at residue 224. Label d indicates a decrease consistent with progressive C terminus degradation of
plasma tau from residue 224 to microtubule binding region upstream region.
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Table 1. Demographics and biomarkers values



















n 9 8 2 5 8 2 31 11 20 24 6
Age, yr 44 (12) 74 (5) 71 (3) 75 (5) 81 (7) 75 (2) 73 (5) 75 (8) 74 (6) 76 (6) 74 (8)
Gender
(F/M)
6/3 5/3 2/0 1/4 5/3 2/0 16/15 2/9 10/10 11/13 1/5
CDR 0 0 0.5 0 0.5 1 0 0.5 0 0.5 1






















































































4.27 (1.71)* 2.21 (0.58) 2.13
(0.09)ns





2.6 (0.2) 2.7 (0.3) 2.7 (0.8)ns 7.0 (1.3)**** 8.7 (1.9)
****
9.3 (0.8)* 2.0 (0.5) 2.0
(0.4)ns





54 (5) 59 (5) 56 (20)ns 187 (42)**** 247 (58)
****






13.5 (0.9) 13.3 (0.8) 14.2
(1.5)ns
16.0 (2.0)** 17.5 (1.9)
****






286 (33) 295 (30) 281 (44)ns 438 (119)*** 501 (93)
****





2.5 (1.2) 2.0 (0.5) 3.3 (1.1)ns 2.1 (0.7)ns 1.8
(0.6)ns










20.4 (6.3) 21.2 (5.2) 22.0 (5.2) 22.7 (6.9) 23.5 (7.4)
p-tau-217/
T217 (%)
































6.8 (1.5) 8.9 (1.5) 8.5 (1.3)ns 12.5 (2.5)*** 13.8 (1.8)
****





1.6 (0.6) 2.0 (0.4) 1.6 (0.1)ns 3.4 (0.9)** 4.3 (2.3)
***





4.0 (1.0) 5.3 (1.1) 3.9 (0.1)ns 4.8 (1.4)ns 4.4 (1.3)ns 3.7 (0.4)ns na na na na na
Data are shown as mean (SD). Superscript parenthetical numbers, e.g., (7), indicate the number of available measures into the group; each participant has at
least one measure (amyloid PET imaging or CSF42/40) used to define amyloid status. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. na, not available;
ns, not significant per the Mann–Whitney test against control groups; F, female; M, male; PiB, Pittsburgh compound B.
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times, respectively) in peripheral tau compared with CSF from
amyloid-negative controls. For p-tau-202, the significant in-
crease of pS202/S202 ratio in plasma (1.7 times) suggests that
peripheral tau is more phosphorylated at this site than in CSF.
We consistently found that the less the site is phosphorylated in
peripheral tau compared with normal CSF, the greater the CNS
tau change would impact plasma levels for the corresponding
tau isoform. This may explain why CSF and plasma p-tau-217
levels better correlate than p-tau-181 levels and the absence of
correlation found for pS202.
Finally, by hypothesizing that peripheral tau does not contain
significant amounts of p-tau-217, we estimated that CNS tau
contributes to ∼20% of the overall plasma t-tau level in controls.
Assuming CNS tau release could increase by three times in AD
(Fagan et al., 2007; Zetterberg, 2017), a higher CNS AD tau
contribution is unlikely to increase AD plasma t-tau levels
by >40%. Moreover, peripheral tau levels could be affected by
different biological factors, potentially interfering with CNS tau
contributions to changes in plasma. This important contribution
of peripheral tau on plasma tau isoforms is a potential source of
interference for assessing effects of tau-directed therapies using
plasma tau biomarkers.
Together, these findings support the use of more specific CNS
tau isoforms such as p-tau-217 and p-tau-181 over t-tau or p-tau-
202 to overcome the contribution of peripheral tau and to
monitor CNS tau in plasma. Plasma measures of p-tau-181 have
been reported to significantly increase in AD particularly at
symptomatic stages, detecting AD with good accuracy (Mielke
et al., 2018; Janelidze et al., 2020a; Thijssen et al., 2020). Our
results suggest that, as reported in CSF (Barthélemy et al.,
2020a; Barthélemy et al., 2020b; Janelidze et al., 2020b),
p-tau-217 in plasma would be more accurate than p-tau-181 for
detecting abnormal CNS tau metabolism.
Limitations and perspectives
One of the limitations of this study is the moderate size of the
study cohort (n = 126 in discovery and validation cohorts). Al-
though the validation cohort reduced the sample volume needed
to 4 ml, this volume remains a restriction. Although clinical
plasma samples of 4 ml are routinely obtained in single collec-
tion tubes, research biorepositories typically share 0.5 ml with
requesters, limiting our current access. In addition, the volume
of plasma currently needed for the plasma p-tau MS assay may
prevent its application for retrospective analyses of plasma
Figure 2. Plasma tau and p-tau changes across groups in Tau SILK discovery cohort. (A)Measures of p-tau-217/T217 ratios in plasma and CSF are highly
correlated in both entire cohort and CSF p-tau-217 positive subgroup. Spearman correlations and associated P value are shown. (B–E) Separation between
amyloid-negative and -positive groups are calculated using AUROC. (B and C) Consistent with CSF measurement, plasma p-tau-217/T217 ratio and p-tau-217
level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative groups with high CSF p-tau-217 were also
separated from other amyloid-negative groups. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181
ratio and p-tau-181 level increase in amyloid-positive groups. YNC, young normal controls; AMC, aged-matched controls.
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Table 2. Abnormal phosphorylation status detected in AD CSF tau (Aβ+) is recapitulated in plasma tau
n t-tau pT217/T217 p-tau-217 level pT181/T181 p-tau-181 level pS202/S202
Tau SILK discovery cohort
AUROC



































CSF vs. plasma: Aβ+ 15 0.29ns 0.71** [0.31–0.89] 0.39ns
[−0.16–0.76]
0.54* [0.02–0.82] 0.19ns 0.04ns
Percent difference relative to controlsa
CSF
All Aβ+ vs. controls 15 vs.
17
188 (110)ns 215 (31)ns 791 (110)**** 25 (18)**** 252 (110) −14 (57)****
Aβ+/CDR = 0 vs.
controls
5 vs. 17 112 (90)ns 167 (27)ns 450 (84)*** 19 (19)* 154 (97) −6 (59)*
Aβ+/CDR = 0.5 vs.
controls
8 vs. 17 146 (83)ns 235 (30)ns 683 (71)**** 30 (18)**** 213 (79) −19 (57)****
Plasma
All Aβ+ vs. controls 15 vs.
17
29 (58)**** 342 (68)**** 506 (95)**** 74 (39)** 128 (80) −4 (55)****
Aβ+/CDR = 0 vs.
controls
5 vs. 17 20 (53)ns 228 (56)** 285 (56)*** 60 (43)ns 86 (58) −5 (55)ns
Aβ+/CDR = 0.5 vs.
controls
8 vs. 17 29 (61)ns 282 (73)**** 379 (93)**** 78 (36)ns 136 (85) −4 (54)**
CSF/plasma ratio
All cohort 34 102 (31) 4.1 (1.2) 418 (197) 1.6 (0.5) 160 (62) 0.5 (0.2)
Aβ− 19 99 (22) 4.6 (1.2) 435 (101) 1.8 (0.5) 178 (57) 0.6 (0.3)
Aβ+ 15 106 (39) 3.6 (1.3) 396 (272) 1.3 (0.2) 136 (60) 0.5 (0.2)
Aβ SILK validation cohort
AUROC
CSF
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cohorts from existing biobanks with limited plasma resources.
Although the protocol used for the validation study using 4 ml of
plasma (∼8 ml whole blood) would be challenging with current
plasma biobanks, changes in plasma collection volume would be
compatible for future studies. In its current form, the assay
would still be significantly less costly and invasive than a PET
scan or lumbar puncture. Our data suggest that plasma t-tau
may not be an accurate AD biomarker with current methods
due to the lower correlation with CSF t-tau. However, significantly
higher plasma t-tau levels in AD were detected in another study
(Mielke et al., 2017). Nevertheless, the magnitude of p-tau-217
changes detected and its high correlation with CSF results dem-
onstrate promising clinical utility for a plasma test specific for
p-tau-217 epitope. We observed plasma p-tau-181 accuracy was
lower in the validation cohort than the discovery cohort and recent
studies using immunoassays (Janelidze et al., 2020a; Thijssen et al.,
2020). We hypothesize the CSF collection (6 ml/h collected by
catheter for Aβ SILK monitoring) occurring in parallel of the
plasma collectionwould have contributed to a reduction of CNS tau
release to the periphery for this particular cohort. No concomitant
CSF collection occurred at the time of the plasma collection used for
the discovery cohort. Thus, the increase of CNS p-tau isoforms
would have been attenuated, affecting mainly p-tau-181, which is
more subject to peripheral tau interference than p-tau-217.
This plasma tau MS assay may be applicable beyond AD to a
wider array of neurodegenerative diseases, especially if com-
bined with a plasma Aβ MS assay. The use of plasma p-tau bi-
omarkers in combination with direct measurement of plasma
amyloid 42/40 ratio would improve the specificity of the test and
enable differential diagnosis of pure tauopathies versus diseases
with mixed pathologies. This clinical application has recently
been reported for plasma p-tau-181 measured by immunoassay
(Janelidze et al., 2020a; Thijssen et al., 2020). Alternatively, this
plasma p-tau assay could be used as a highly sensitive screening
tool to identify a high risk of amyloidosis in normal subjects,
replacing costly PET imaging. Further work is needed to deter-
mine the relationship and timing of plasma p-tau changes
compared with plasma Aβ (Ovod et al., 2017; Nakamura et al.,
2018; Schindler et al., 2019) and other biomarkers (Preische
et al., 2019) for more accurate staging of the disease. For diag-
nostic validation, confirmation for amyloid status or diagnosis
for AD could then be obtained by CSF biomarkers, amyloid and
tau PET measurements, or brain neuropathology.
Conclusion
We demonstrate that measuring attomolar concentrations of tau
isoforms in plasma is feasible using an enrichment protocol and
MS. Our results indicate that changes in plasma p-tau, especially
p-tau-217, mirror highly specific modifications in CSF to detect
phosphorylation changes in soluble tau and amyloidosis. We
provide strong evidence of a peripheral contribution to blood tau
in plasma, which has a different phosphorylation profile com-
pared with CSF. These findings support blood p-tau isoforms




The tau SILK studies had enrolled 58 participants for tau kinetic
measurements at the time of our study (Sato et al., 2018). These
studies were approved by the Washington University in St. Louis
Institutional Review Board.Written informed consent was obtained
fromall participants before inclusion in the study. Participantswere
identified by number, not by name. Control participants were re-
ferred fromVolunteer for Health atWashingtonUniversity. AD and
age-matched control participants with cognitive measures and
amyloid and tau PET scans were referred from the Knight Alz-
heimer’s Disease Research Center andMemory Diagnostic Center at
Washington University in St. Louis. During the tau SILK study,
participants received 16 h of labeled 13C-leucine infusion followed by
five lumbar punctures to collect CSF over the next 4 mo (Sato et al.,
2018). To monitor leucine enrichment in the periphery, ∼10 ml of
plasma was collected at each of the 12 time points performed over
19.5 h during the infusion procedure (Potter et al., 2013).
Discovery cohort
CSF from the 58 SILK participants was analyzed by MS for CSF
Aβ42/40 and tau isoforms as previously reported (Patterson
et al., 2015; Barthélemy et al., 2019; Sato et al., 2018). Plasma
samples from 34 participants were selected based on their am-
yloid and cognitive status, as described in Table 1. 11 of these
Table 2. Abnormal phosphorylation status detected in AD CSF tau (Aβ+) is recapitulated in plasma tau (Continued)
n t-tau pT217/T217 p-tau-217 level pT181/T181 p-tau-181 level pS202/S202
CSF vs. plasma: Aβ+ 50 0.03ns 0.59****
[0.36–0.75]
0.25ns 0.22ns 0.08ns

















Data are shown as mean (SD) for % of increase compared to control value and ratio and as value (95%, CI) for AUROC and Spearman r. *, P < 0.05; **, P < 0.01;
***, P < 0.001; ****, P < 0.0001. ns, not significant per the Mann–Whitney test against aged and normal control groups (amyloid-negative participants without
cognitive symptoms). Numbers in brackets indicate confidence intervals for AUROC.
aStatistical significance (t test using the linear step-up procedure of Benjamini, Krieger, and Yekutieli) of the change compared to p-tau-181 level change as
reference.
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participants were identified as amyloid-positive using amyloid
AV45 PET (cutoff 1.3). Four additional amyloid-positive partic-
ipants with no amyloid PET data were identified by CSF42/40
ratio (cutoff 0.086 established using results from participants
with AV45 PET data). The 15 amyloid-positive participants had
clinical dementia rating (CDR) scores of 0 (5 participants), 0.5
(8 participants), and 1 (2 participants). All preclinical AD par-
ticipants (amyloid-positive, CDR = 0) had tau PET AV-1451
standardized uptake value (SUVR) measures not significantly
different from amyloid-negative participants (Table 1). The 41
remaining participants were amyloid-negative by AV45 PET
when available or by CSF Aβ42/40. 17 of these participants were
selected as controls (9 young controls and 8 randomly selected
aged controls). Two participants identified as MCI were also
included. The number of participants for this plasma cohort was
34 total. Of note, all amyloid-positive participants were abnor-
mal for CSF pT217/T217 ratio (cutoff 4.6%), though this variable
was not considered for sample selection.
Validation cohort
CSF and plasma from 92 participants collected from Aβ SILK
studies (Patterson et al., 2015; Ovod et al., 2017) were analyzed
Figure 3. Plasma tau and p-tau changes across groups in Aβ SILK validation cohort. (A) Phosphorylation occupancies on T217 in plasma and CSF
correlate. Spearman correlations and associated P value are shown. (B and C) As found in the discovery cohort, plasma p-tau-217/T217 ratio and p-tau-217
level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative with high CSF p-tau-217 were also
separated from other amyloid-negative groups. Separations between groups are calculated using AUROC. (D) Plasma tau level is not a biomarker for amyloid
status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups but are less accurate than p-tau-217
measures to detect abnormal tau phosphorylation. (G and H) Receiver operating characteristic curves discriminating amyloid-positive from amyloid partic-
ipants using CSF and plasma tau measures. Corresponding AUCs are summarized in Table 2. AUC comparison between p-tau-217 and p-tau-181 measures is
described in Table S3. (I) Plasma p-tau-217/T217 ratio associates with Aβ42/40 ratio measured in CSF.
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for tau isoforms as the validation cohort. The Aβ SILK protocol
involved blood and CSF collection at baseline, followed by a
leucine bolus and infusion over 9 h. Blood (12 ml) and CSF (6 ml)
samples were obtained hourly over 36 h, aliquoted at 1 ml in
polypropylene tubes, and stored at −80°C CSF until use. Aliquots
collected at hour 32 were used for the MS measurement of tau
isoforms. For plasma, 1-ml aliquots collected after hour 16 were
combined for constituting 4-ml plasma samples. Amyloid status
was defined by CSF Aβ42/40 (cutoff 0.139), when available (n =
66), and amyloid PET centiloid from Pittsburgh compound B
tracer or AV45 SUVR. Under this definition, all amyloid-positive
participants (n = 50) had elevated CSF pT217/T217 ratio (cutoff
2.75%) and 41 of the 42 amyloid-negative participants had CSF
pT-217/T217 below this cutoff. Amyloid groups were divided into
clinical groups according to their CDR status.
Plasma and CSF tau immunopurification (IP)-LC-MS analysis
Frozen plasma aliquots of 1 ml were thawed at 4°C overnight. For
the discovery study, ∼20 ml of plasma was pooled by combining
20 tubes of 1-ml plasma aliquots from the same participant from
the 16-h infusion. After 16,000 g centrifugation for 30 min at 4°C,
20 ml was transferred into a new tube, and samples were spiked
with 1 ng of 15N-labeled recombinant 2N4R tau internal standard
(gift from Guy Lippens, Centre national de la recherche scienti-
fique, Université de Lille, Villeneuve-d’Ascq, France). Plasma
proteins were precipitated with perchloric acid (3.5% vol/vol fi-
nal), vortexed to homogenize, and incubated for 30 min on ice.
Samples were then centrifuged for 30 min at 4°C at 16,000 g.
Supernatants containing soluble tau (Barthélemy et al., 2016)were
transferred to new tubes and spiked with trifluoroacetic acid
(TFA) to a final concentration of 1%. Samples were loaded on an
Oasis HLB VAC RC 30-mg extraction cartridge (Waters) initially
conditioned with 1 ml MeOH and 1 ml 0.1% TFA. After loading,
samples were desalted with 1 ml 0.1% TFA and then eluted with
700 µl 27.5% acetonitrile-0.1% TFA solution. Eluates were lyoph-
ilized by speed-vac and then reconstituted in 1 ml 1× PBS, 1×
protease inhibitor cocktail (Roche), 1% NP-40, and 5 mM guani-
dine. After this step, both plasma and thawed CSF (spiked with
15N-tau and IP reagents) were IP using similar protocol as pre-
viously reported for CSF (Sato et al., 2018; Barthélemy et al., 2019).
Briefly, CSF and plasma tau were immunoprecipitated with Tau1
and HJ8.5 antibodies, then digested with trypsin. Digests were
spikedwith absolute quantification peptides (Life Technologies) to
50 and 5 fmol for each unphosphorylated and phosphorylated
peptide, respectively. Tryptic digest was purified by solid phase
extraction on C18 TopTip. The eluate was lyophilized and re-
suspended in 25 µl before nano-LC-MS/high resolution MS
analysis on nanoAcquity ultra performance liquid chromatogra-
phy system (Waters) coupled to an Orbitrap Tribrid Eclipse mass
spectrometer (Thermo Fisher Scientific) operating as previously
reported (Barthélemy et al., 2020a). Tandem MS (MS/MS) tran-
sitions from ionized peptides (Table S2) were recorded using
parallel reaction monitoring and extracted at 5 ppm using Skyline
software (MacCoss Lab, University of Washington, Seattle, WA).
The internal calibration of tau and p-tau levels was per-
formed in two steps. First, the addition of 15N-tau internal
standard to plasma before the first extraction step allows the
measurement of absolute level of each unmodified tau peptide in
plasma using LC-MS area ratio between each endogenous tau
peptide and 15N-tau peptide. Second, the phosphorylation oc-
cupancy for each modified residues was obtained by comparison
of the endogenous p-tau/tau ratio with p-tau/tau ratio measured
on corresponding unphosphorylated and phosphorylated abso-
lute quantification synthetic peptide standard labeled at lysine
or arginine on the C-terminal position of the tryptic peptide. The
determination of p-tau level was obtained by combination of
t-tau level and p-tau/tau phosphorylation occupancy.
Performance of the 4 ml starting volumewas assessed using a
spike and recovery experiment on plasma pools from healthy
volunteers. Coefficients of variation measured on plasma bio-
logical replicates without CSF spikes for t-tau, p-tau-217 and
p-tau-181 were all below 7% (Fig. S1 and Table S1). LC-MS/MS
responses for the different plasma tau measures were propor-
tional to the amount of control and AD CSF successively added.
We measured 15N-tau protein internal standard recovery ob-
tained after plasma extraction (chemical extraction + IP) and
compared with the recovery obtained after IP of the same
amount of standard spiked in recombinant human serum albu-
min (HSA) 5% solution. We found the plasma protocol recovered
from 30 to 50% of the amount recovered by IP only. This protein
recovery is similar to previous assessment on tau chemical ex-
traction protocol in CSF (Barthélemy et al., 2016).
Statistics
All statistical analyses were performed using GraphPad Prism
software (v8.3.0.) The Mann–Whitney test was used for com-
paring p-tau/tau ratios and levels across subgroups of AD and
control. Spearman correlations were used to analyze correla-
tions between plasma and CSF tau. Paired t was used to test the
differences in the percentage change relative to control group
between p-tau-181 (reference biomarker) and other biomarkers.
P values were adjusted using the two-stage step-up method of
Benjamini, Krieger, and Yekutieli to control the false discovery
rate. Data are represented as mean ± SD unless otherwise
specified. Significance of the AUROC was assessed using the
DeLong test.
Online supplemental material
Fig. S1 shows spike and recovery experiment validating the
analytical performance for the plasma assay using 4 ml of
sample. Table S1 shows replication in non-spiked plasma pool
from healthy volunteers and method performance measured in
the spike and recovery experiment. Table S2 shows peptides
sequences and corresponding MS/MS transitions used for the
quantitation of plasma tau peptides. Table S3 shows AUC com-
parison by DeLong test on p-tau217 and p-tau181 performance in
separating amyloid positive from amyloid negative.
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Supplemental material
Tables S1–S3 are provided online as separate Word documents. Table S1 shows replication in non-spiked plasma pool from healthy
volunteers and method performance measured in the spike and recovery experiment. Table S2 shows peptides sequences and
correspondingMS/MS transitions used for the quantitation of plasma tau peptides. Table S3 shows AUC comparison by DeLong test
on p-tau217 and p-tau181 performance in separating amyloid positive from amyloid negative.
Figure S1. Spike and recovery experiment assessing assay performance using 4 ml of plasma volume. Plasma pool or 5% solution of recombinant HSA
were spiked with increased volumes of AD or non-AD CSF pools. Plasma was extracted using the 4-ml protocol described in the Materials and methods. HSA
samples were only immuno-purified (IP) before digestion and analysis.
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